

## For Immediate Release

### **Net Profit up 274 %, Net Revenues up 85%**

**Vadodara, 27<sup>th</sup> October, 2015**

Alembic Pharmaceuticals Limited reported its performance for the Second quarter ending 30<sup>th</sup> September 2015. The audited results were taken on record by the Board of Directors at a meeting held in Vadodara today.

#### **Financial Highlights**

- Net Sales up 85% to Rs 1018 Crore
- Net Profit up 274% to Rs 289 Crore
- International Generics up 342% to Rs 559 Crore
- API Business up 43% to Rs 137 Crore

**Commenting on the results, Mr. Shaunak Amin, Joint Managing Director, Alembic Pharmaceuticals Limited said** “We have seen exceptional growth due to the Aripiprazole Day 1 Launch in the US. Our facilities have been in compliance and we have received 9 ANDA approvals this year.”

#### **Operational Highlights**

##### **India Branded Formulations**

- The India Branded formulations business at Rs 285 crores
- Specialty Segment grew by 21% and Acute Segment de-grew by 9%. Within specialty segment Cardiology, Anti Diabetic and Gynaecology grew impressively by 34%, 31% and 26% respectively
- Alembic’s “Tellzy” is the fastest growing (50% as per ORG MAT Sep 2015) Telmisartan brand and is now the 3<sup>rd</sup> ranked brand in the Telmisartan market

##### **International Generics**

- Successful Launch of Aripiprazole Generic on Day 1
- International Generics grew by 342% to Rs 559 crores in the quarter
- USA front end launched
- During the quarter 2 ANDA approvals were received
- 3 ANDA applications were filed during the quarter, taking cumulative ANDA filings at 71
- 2 DMF applications were filed during the quarter, taking cumulative DMF filings at 75

Summary of Total Revenue is as under:

(Rs in Lacs)

Particulars	Q2 FY16	Q2 FY15	H1 FY16	H1 FY15	% Change
<b>Formulation</b>					
India Branded	28460	27551	54735	49879	10%
India Generics	2510	3222	5369	5744	(-)7%
International Branded	1163	1865	2008	4175	(-)52%
International Generics	55925	12643	73013	24352	200%
<b>API</b>	13716	9594	25681	20338	26%
<b>Total</b>	<b>101774</b>	<b>54875</b>	<b>160806</b>	<b>104488</b>	<b>54%</b>

The Profit break-up is as under:

(Rs in Lacs)

Particulars	Q2 FY16	Q2 FY15	H1 FY16	H1 FY15	% Change
EBITDA	37603	10743	47809	20345	135%
Profit Before Tax	36208	9569	45066	18062	150%
Net Profit after Tax	28890	7727	35877	14194	153%

About Alembic Pharmaceuticals Limited

Alembic Pharmaceuticals Limited, a vertically integrated research and development pharmaceutical company, has been at the forefront of healthcare since 1907. Headquartered in India, Alembic is a publicly listed company that manufactures and markets generic pharmaceutical products all over the world. Alembic's state of the art research and manufacturing facilities are approved by regulatory authorities all over the world including the US FDA. Alembic is one of the leaders in branded generics in India. Alembic's brands, marketed through a marketing team of over 5000 are well recognized by doctors and patients.

Information about the company can be found at [www.alembic-india.com](http://www.alembic-india.com); (reuters:ALEM.NS) (bloomberg:ALPM) (nse:APLLTD) (bse:533573)

**For more information contact:**

<b>Ajay Kumar Desai</b> Phone: +91 22 – 306 11681 Email: <a href="mailto:ajay.desai@alembic.co.in">ajay.desai@alembic.co.in</a>	<b>Mitanshu Shah</b> Phone: +91 265 – 3007630 Email: <a href="mailto:mitanshu.shah@alembic.co.in">mitanshu.shah@alembic.co.in</a>
---	---